• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Avadel Pharmaceuticals plc

    6/18/25 7:03:06 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVDL alert in real time by email
    DEFA14A 1 tm2516079d3_defa14a.htm DEFA14A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )

     

    Filed by the Registrant x    Filed by a party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

     

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨ Definitive Proxy Statement

     

    x Definitive Additional Materials

     

    ¨ Soliciting Material under §240.14a-12

     

    AVADEL PHARMACEUTICALS PLC
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required.

     

    ¨ Fee paid previously with preliminary materials.

     

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

    GRAPHIC

    Step 1: Go to www.envisionreports.com/AVDL. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/AVDL Online Go to www.envisionreports.com/AVDL or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 045RSA Important Notice Regarding the Availability of Proxy Materials for the Avadel Pharmaceuticals plc Shareholder Meeting to be Held on July 29, 2025. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Proxy Statement, 2024 Annual Report and 2024 Irish Statutory Financial Statements are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before July 18, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by 10:00 am Irish Standard Time on July 28, 2025. MMMMMMMMMMMM MMMMMMMMM 000001MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 COY MMMMMMM

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/AVDL. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Avadel Pharmaceuticals plc” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by July 18, 2025. The Avadel Pharmaceuticals plc Annual Meeting of Shareholders will be held on July 29, 2025, 10:00 AM (Irish Standard Time) at Ten Earlsfort Terrace, Dublin 2, D02 T380 Ireland. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR the election of each director nominee and FOR Proposal 2: 1. Election of Directors: 01 - Gregory J. Divis 02 - Dr. Eric J. Ende 03 - Geoffrey M. Glass 04 - Dr. Mark A. McCamish 05 - Linda S. Palczuk 06 - Peter J. Thornton 07 - Dr. Naseem S. Amin 2. To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company’s independent registered public auditor and accounting firm for the fiscal year ending December 31, 2025, and to authorize, in a binding vote, the Audit Committee of the Board of Directors to set the independent registered public auditor and accounting firm remuneration The Board of Directors will consider and act upon any other business as may properly come before the meeting or any adjournment or postponement thereof. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Shareholder Meeting Notice

    Get the next $AVDL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVDL

    DatePrice TargetRatingAnalyst
    7/18/2025$22.00Buy
    H.C. Wainwright
    2/11/2025$12.00Buy
    Deutsche Bank
    6/12/2024$27.00Buy
    Rodman & Renshaw
    3/5/2024$27.00 → $29.00Outperform
    Oppenheimer
    3/5/2024$21.00 → $25.00Buy
    H.C. Wainwright
    3/5/2024$20.00 → $22.00Buy
    Needham
    2/6/2024$21.00Buy
    UBS
    11/30/2022$6.50 → $11.00Hold → Buy
    Jefferies
    More analyst ratings

    $AVDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Avadel Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    7/18/25 9:08:21 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Avadel Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    2/11/25 7:00:38 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00

    6/12/24 7:06:25 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

    DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Wednesday, September 10 at 9:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel's Invest

    8/29/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the

    8/7/25 4:05:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/22/25 4:13:34 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:24:12 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:22:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccamish Mark Anthony was granted 11,000 units of Ordinary Shares, increasing direct ownership by 100% to 22,000 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:10:52 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Palczuk Linda was granted 11,000 units of Ordinary Shares, increasing direct ownership by 16% to 78,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:09:56 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. was granted 11,000 units of Ordinary Shares, increasing direct ownership by 11% to 115,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:09:06 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc

    SCHEDULE 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    8/14/25 11:00:36 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Avadel Pharmaceuticals plc

    S-8 - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    8/7/25 4:28:29 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Avadel Pharmaceuticals plc

    S-3ASR - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    8/7/25 4:06:53 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Financials

    Live finance-specific insights

    View All

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

    DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are

    7/31/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

    -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

    5/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Leadership Updates

    Live Leadership Updates

    View All

    Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

    DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. "Susan is an accomplished biopharma executive with a track record of strategic leadership and excellence in commercializing innovative medicines," said Gregory J. Divis, Chief Executive Officer of Avadel. "Her expertise will be invaluable at this critical

    5/13/25 4:15:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

    DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build

    2/24/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

    DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin

    1/22/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/14/24 6:10:30 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:58:54 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:00:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care